China -  Chinese law firm

Vol.3, No.27

CHINA HEALTH SCIENCES NEWSLETTER

Vol. 3 , No.27 - December 20, 2002

 

TOPICS THIS ISSUE:

  • Trades and Services Undergo Change
  • Health Reform Eases Cash Burden
  • Biotech's Yin and Yang
  • Foreign Invested Anti-HIV Drugs tend to be Economical
  • China gives go-ahead to First State-Run Stem Cell Bank
  • China Imports and Exports More Medicine

Trades and Services Undergo Change

Change of the examination and approval system for new medicines will have a big impact on Chinas pharmaceutical enterprises. The Regulation on the Implementation of Medicine Management Law that became effective on September 15 has introduced a series of reforms to the examination and approval of new medicines, including re-definition of new medicines. The concept of new medicines will change from those that are produced for the first time in China to those that are on sale for the first time in China.

All in all, the new definition has resolved the problem encountered by old medicine in new names. Reducing the complexity in obtaining approval of new medicines has secured reasonable profits for new medicines and facilitated the entry of foreign new medicines into the Chinese market.

(Source: Xinhua Economic News Service)

Health Reform Eases Cash Burden

A total of 100 million people are expected to be covered by the new basic medical insurance system in China by the end of next year. Experts said the benefits would mainly be felt by urban dwellers, leaving millions of rural residents to rely on a fledgling cooperative insurance system.

According to the new system, people can visit doctors at any hospitals covered by the system and buy medicines in drug stores.

The basic medical insurance system initiated in 1998, is currently established in about 98% of the country's urban areas, and 86.9 million workers or retired people in cities and towns have joined. More than 70% of urban dwellers are supported by the system, a reform of the free medical care system, according to a survey in 10 cities conducted by the Ministry of Labor and Social Security.

Under the old practice, employers paid almost all medical fees of company employees or governmental staff in towns and cities. However, the new medical insurance system collects money from government, employers and employees who share the medical burden. Urban workers and retirees will benefit most. People in rural areas, who account for about 70 percent of the population of China, must wait for a "cooperative medical service insurance system" that is still undergoing trials.

Official statistics show that the system has so far worked well in 2002. In the first 10 months of this year, the foundation derived income of RMB 46.6 billion (US$ 5.6 billion) and expenditure of RMB 31.3 billion (US$ 3.77 billion). But many problems still exist. Wang Jianlun, former vice-minister of the Ministry of Labor and Social Security said the quality of medical service management is poor and is even beginning to hinder the process of reform.

The basic medical insurance excludes no illness, said Xiong Xianjun, chief of the medical insurance division under the Ministry of Labor and Social Security. Xiong stressed that AIDS patients enjoy the same coverage as others. However, he pointed out that AIDS patients and HIV carriers may still confront many difficulties when requesting additional medical insurance assistance due to prejudices and the misinterpretation of policies with none of the anti-AIDS drugs having been incorporated into the list of medicines covered by the medical insurance system.

(Source: Business Daily Update)

 


Please contact us for Business development and Pharmaceutical licensing opportunities
wzhao@lehmanlaw.com or Camilla@lehmanlaw.com

is the agent of in China. Pharmalicensing is a web-based company that provides highly efficient marketing tools for companies in the pharmaceutical and biotech industries. Pharmalicensing aims to increase awareness of your company through their large business development audience and to proactively match and forward to your company potential out-licensing, in-licensing- and cooperation partners.

 

 

 

 


Biotech's Yin and Yang

China's economy may be booming on the back of manufacturing but the government wants future growth to come more from high technology and knowledge-based industries. So, between 1996 and 2000, the central government invested in excess of RMB 1.5 billion (US$ 180 million) in biotechnology, as part of its attempts to develop its biotechnology sector. Between 2000 and 2005, the central government plans to invest another RMB 5 billion. As a result, the Science Ministry claims that as many as 20,000 researchers work in the life sciences in China.

The Chinese government spent RMB 322 million on plant-biotechnology research alone in 2000, sustaining one of the biggest public-sector agricultural-science programmes in the world.

These figures may not be very impressive when compared with the US$ 15.7 billion invested in research and development last year alone in the United State's biotechnology industry, which employs 191,000 people. But the speed with which China's industry is growing provokes both wonder and anxiety in the outside world. Some worry that a lack of public debate over biotechnology, and different philosophical traditions, mean that China will head off in directions that are morally unacceptable in the West.

Chinese biotech development is balanced by several opposing forces, including a lack of some of the basic building-blocks of a modern, knowledge-driven industry, ever-shifting regulation, particularly for genetically modified (GM) crops, and the first stirrings of protest by activist groups. This balance of opposites, the yin and the yang, is as familiar a feature of the country's modern technological development as it is of ancient Chinese philosophy.

Tight new regulations were announced last year governing food labeling, environmental testing, commercial release, and the import and export of GM crops. The new import rules include requirements for field-testing and a food safety evaluation. Some scientists argue that this more cautious stance is justified, given that China's next generation of GM crops includes such staple foods as rice, which could be adopted by billions of people around the world, and whose safety now rests in China's hands.

However, coverage of GM foods in China is still more muted than in the West. As Dr Huang points out, the "public" debate over biotechnology in China still means exchanges among scientists and government officials, rather than society at large.

In Beijing's top hospitals you will find many of the fruits of biotechnology, such as genetically engineered insulin to treat diabetes or interferon-alpha to fight cancer. In fact, there are now approximately 20 genetically engineered medicines approved for sale in China, generating RMB 7.6 billion in revenue in 2000. Yet although these genetically engineered drugs were made in China, such products are little more than high-tech knock-offs of rich-country inventions, introduced when China had little interest in intellectual-property rights.

Wang Hongguang, director of the National Centre for Biotechnology Development, admits that originality is still a problem for many of China's scientists. He hopes the return of some of the 20,000 Chinese researchers now working abroad will add a spark of creativity. Last month, Beijing announced a recruitment drive to attract 200 scientists from abroad with the promise of western-style salaries.

For all these scientific strengths, the expansion of Chinese biotechnology is held back by several problems. One is funding. Biotechnology is not cheap, with long development times and scientific uncertainty means that it takes lots of money to develop a successful product. At the moment, the government funds most Chinese biotechnology projects, although private money is beginning to trickle in.

On the whole, biotech entrepreneurs would rather have private money than deal with the strings that inevitably come with public funds. So far, private investors in China are far less sophisticated than their foreign counterparts. Some investors from Taiwan, Singapore and Hong Kong have taken the plunge. But venture-capital groups from Europe and America are holding off until they can be assured of a way to recoup their investment, preferably by floating any resultant company on the stockmarket, or selling it to a larger firm.

A second problem is management. As in the early days of European biotech, China's emerging industry lacks people who combine scientific nous with good business sense. Another shortcoming is intellectual-property protection. Although China moved last year to strengthen its patent laws for drugs and other biotech products, it is still a hard, expensive slog to get a patent and even harder to protect it.

Lastly, there is the question of regulation. China's patchy record in such bioethical minefields such as abortion and organ donation leads many in the West to fear the worst when they hear that the country is branching into genetic engineering or high-tech reproduction.

(Source: The Economist)

Foreign Invested Anti-HIV Drugs tend to be Economical

Multinational corporations have started to introduce new anti-HIV medicines into China with domestic enterprises, such as Northeast Pharmaceutical Group Sales Co., Ltd. and Shanghai Desano Co. Ltd, beginning to promote anti-HIV medicines which imitate lapsed patent drugs.

The largest overseas investor in pharmaceutical enterprise in China, GlaxoSmithKline (GSK), recently announced that it will launch its HAART tri-compound drug (AZT + 3TC + ABC) Trizivir in China. GSK has also stated that it has submitted an application with the State Drug Administration (SDA) to produce the anti-HIV drug Combivir in China.

Merck Sharp & Dohme (China) has announced that it will release its new EFV 600mg tablet in China in an attempt to realize its promise to lower the prices for HIV treatment drugs to a more acceptable level. This new EFV tablet's dosage is one tablet a day with its price will be capped at US $ 2.10.

(Source: SinoCast China Business Daily News)

China gives go-ahead to First State-Run Stem Cell Bank

China's government has given the go-ahead for the establishment of the country's first state-run stem cell repository.

The repository is to include a stem cell bank and an engineering center located in Tianjin, a port city near Beijing. A stem cell transplant center at the facility will eventually be able to provide transplants for 200 patients every year.

Stem cell is a term used to define a broad category of cells that have the ability to divide for indefinite periods into specialized body cells, such as blood, skin or organ cells.

Transplanting stem cells, usually taken from donors' bone marrow, is considered one of the most effective measures to treat leukemia.

China has also initiated a system of letting parents preserve umbilical cord blood stem cells from newborn babies for possible later medical use.

(Source: Agence France Presse)

China Imports and Exports More Medicine

China imported and exported US$ 7.224 billion worth of Western medicine, medical instruments and meters in the first three quarters of this year, according to Qiao Haili, an official of the China Chamber of Commercial for the Import and Export of Medicinal and Health Products.

China's pharmaceutical exports were valued at US$ 4.168 billion, up 43.46%, while its imports were valued at US$ 3.256 billion, up 39%.

The export of crude drugs was US$ 2.158 billion, up 47.37%, including US$ 94 million of penicillin, up 42.76%, 32,000 tons of vitamin C, and US$ 46 million of paracetamol, up 30%. The export of medical instruments and meters totaled US$ 1.065 billion, up 82%. These exports mainly went to Asia, Europe and the United States.

Conversely, China imported US$ 3.256 billion of Western medicine, medical instruments and meters in the first three quarters of this year, up 39% on last year. This included US$ 1 billion dollars of Western crude drugs, up 124%, US$ 660 million of Western drugs, up 9%, US$ 140 million of biochemical drugs, up 126%, US$ 1.3 billion of medical instruments and meters, up 19%, US$ 16 million of dressings, up 17 % and US$ 80 million of farm chemicals, down 5.17%.

(Source: Xinhua Economic News Service)


Lehman Lee & Xu

A Licensed Chinese Law Partnership

http://www.lehmanlaw.com

Beijing Office

Shanghai Office

6th floor, Dongwai Diplomatic Office Building
23 Dongzhimenwai Dajie
Beijing 100600 China
Tel.: (86)(10) 8532-1919
Fax: (86)(10) 8532-1999
Email: mail@lehmanlaw.com

Suite 1310, Kerry Centre
No. 1515, West Nanjing Road
Shanghai 200040 China

Tel: (86)(21) 6288-2698

Fax:(86)(21) 6288-2699
Email: shanghai@lehmanlaw.com

Shenyang

Hong Kong

Guangzhou

Chengdu

The China Health Sciences Newsletter is intended to be used for news purposes only. It should not be taken as comprehensive legal advice, and Lehman, Lee & Xu will not be held responsible for any such reliance on its contents.

RSS Feeds